10 results match your criteria: "City Clinical Hospital No. 51[Affiliation]"
Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment Elevation Myocardial Infarction: Secondary End Points From an International, Double-Blind, Randomized, Placebo-Controlled, Phase 2a Study.
J Cardiovasc Pharmacol
December 2024
R-Pharm JSC, Medical Department; Moscow, Russia ; and.
In a randomized double-blinded clinical trial of patients with ST segment elevation myocardial infarction (STEMI), goflikicept, an interleukin-1 blocker, significantly reduced systemic inflammation, measured as the area under the curve (AUC) for high-sensitivity C reactive protein at 14 days. We report secondary analyses of biomarkers at 28 days, and cardiac function and clinical end points at 1 year. Patients received a single administration of goflikicept 80 mg (n = 34), goflikicept 160 mg (n = 34), or placebo (n = 34).
View Article and Find Full Text PDFInterleukin-1 blockade with RPH-104 (goflikicept) in patients with ST-segment elevation myocardial infarction (STEMI): secondary endpoints from an international, double blind, randomized, placebo-controlled, phase IIa study.
J Cardiovasc Pharmacol
October 2024
R-Pharm JSC, Medical Department; Moscow, Russia.
Article Synopsis
- A clinical trial evaluated the effects of goflikicept, an IL-1 blocker, in patients with STEMI and found it significantly reduced systemic inflammation measured by hsCRP levels at both 14 and 28 days.
- Two doses of goflikicept (80 mg and 160 mg) showed similar effectiveness in reducing hsCRP without significant differences in cardiac biomarkers or clinical outcomes like death and hospitalization compared to a placebo.
- The study concluded that goflikicept is well tolerated and effectively reduces inflammation but highlighted the need for further research to see if this reduction leads to actual clinical benefits for STEMI patients.
Results of International, Double-Blind, Randomized, Placebo-Controlled, Phase IIa Study of Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment-Elevation Myocardial Infarction (STEMI).
Circulation
August 2024
R-Pharm JSC, Medical Department, Moscow, Russia (S.A.G., A.N.E., E.G.P., M.Y.S.).
Diagnosis and Treatment Patterns of Chronic Thromboembolic Pulmonary Hypertension in Russia, Kazakhstan, Turkey, Lebanon, and Saudi Arabia: A Registry Study.
Drugs Real World Outcomes
March 2024
Department of Pulmonary Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Background: Patients with chronic thromboembolic pulmonary hypertension (CTEPH) in countries with limited resources have, to date, been poorly represented in registries.
Objective: This work assesses the epidemiology, diagnosis, hemodynamic and functional parameters, and treatment of CTEPH in Russia, Kazakhstan, Turkey, Lebanon, and Saudi Arabia.
Methods: A prospective, cohort, phase IV, observational registry with 3-year follow-up (n = 212) in patients aged ≥ 18 years diagnosed with CTEPH was created.
[Left ventricular global function index as a predictor of adverse cardiovascular events in patients with acute coronary syndrome].
Kardiologiia
August 2021
Central State Medical Academy of Department of Presidential Affairs, Moscow; City Clinical Hospital No. 51, Moscow.
Aim To evaluate the prognostic significance of the left ventricular global function index (LV GFI) in patients with acute coronary syndrome (ACS) using echocardiography (EchoCG).Material and methods The LV GFI is an index that integrates LV cavity volumes, stroke volume, and myocardial volume. This study included 2169 patients with ACS (1340 (61.
View Article and Find Full Text PDFRisk Stratification after an Acute Coronary Syndrome: Significance of Antithrombotic Therapy.
J Clin Med
April 2021
Central State Medical Academy of Department of Presidential Affairs, 121359 Moscow, Russia.
The impact of the de-escalation strategy of antiplatelet therapy (APT) on the life expectancy after acute coronary syndromes (ACS) and percutaneous coronary intervention (PCI) requires an assessment in real clinical practice. Into the Russian multicentral observational trial (ORACLE II ClinicalTrials.gov number, NCT04068909), 1803 patients with ACS and PCI indications were enrolled.
View Article and Find Full Text PDF[Myasthenia gravis and muscle atrophy].
Zh Nevrol Psikhiatr Im S S Korsakova
March 2021
Moscow Myasthenic Center of the City Clinical Hospital No. 51, Moscow, Russia.
Muscle atrophy is uncommon in myasthenia gravis. There are some reports in the literature of muscle atrophy in MUSK-positive myasthenia gravis. The authors present eight cases of AChR-positive myasthenia gravis associated with muscle atrophy.
View Article and Find Full Text PDFTicagrelor in Patients with Stable Coronary Disease and Diabetes.
N Engl J Med
October 2019
From the French Alliance for Cardiovascular Trials, Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Université de Paris, INSERM Unité 1148 (P.G.S.), Assistance Publique-Hôpitaux de Paris (P.G.S., T.S.), Hôpital Saint Antoine, Department of Clinical Pharmacology, Unité de Recherche Clinique (T.S.), and Sorbonne Université (T.S.) - all in Paris; the National Heart and Lung Institute, Imperial College and Royal Brompton Hospital, London (P.G.S., K.F.); Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School (D.L.B.) and Baim Institute for Clinical Research (Y.L.) - both in Boston; the Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, ON (S.R.M.), and Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.) - both in Canada; Stanford University, Stanford, CA (R.A.H.); the Department of Medical Sciences, Cardiology, Uppsala Clinical Research Center, Uppsala University, Uppsala (C.H.), and AstraZeneca BioPharmaceuticals Research and Development, Mölndal (M.A., A.H., W.R., M.L.-Z.) - both in Sweden; the Department of Cardiology, Medical University of Warsaw, Warsaw, Poland (G.O.); City Clinical Hospital No. 51, State Health Care Agency, Moscow (D.Z.); Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China (J.G.); Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo (J.C.N.); Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile (R.C.); Northwest Clinics, Department of Cardiology, Alkmaar, Dutch Network for Cardiovascular Research, Utrecht, and Department of Cardiology, Radboud University Medical Center, Nijmegen - all in the Netherlands (J.H.C.); and Cardiocenter Charles University, Third Faculty of Medicine, University Hospital Kralovske Vinohrady, Prague, Czech Republic (P.W.).
Background: Patients with stable coronary artery disease and diabetes mellitus who have not had a myocardial infarction or stroke are at high risk for cardiovascular events. Whether adding ticagrelor to aspirin improves outcomes in this population is unclear.
Methods: In this randomized, double-blind trial, we assigned patients who were 50 years of age or older and who had stable coronary artery disease and type 2 diabetes mellitus to receive either ticagrelor plus aspirin or placebo plus aspirin.
Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants.
Br J Anaesth
April 2018
Primary Vascular Department, City Clinical Hospital No. 51, Moscow, Russia.
Non-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran) and factor Xa (rivaroxaban, apixaban, edoxaban) have been introduced in several clinical indications. Although NOACs have a favourable benefit-risk profile and can be used without routine laboratory monitoring, they are associated-as any anticoagulant-with a risk of bleeding. In addition, treatment may need to be interrupted in patients who need surgery or other procedures.
View Article and Find Full Text PDFLymphotropic administration of photosensitizer as a model of target therapy of testicle inflammation: Experimental and clinical data.
Photodiagnosis Photodyn Ther
March 2016
A.M Prokhorov General Physics Institute of Russian Academy of Sciences, 119991, Vavilov St.,38, Moscow, Russia; National Research Nuclear University (Moscow Engineering Physics Institute) MEPhI, 115409, Kashirskoe highway 31, Moscow, Russia.
Background: The existence of zones of humoral skin-subskin tissue linkage with internal organs as well as the possibility of targeted administration of preparation into the affected organs were studied.
Methods: An experimental study of preparation and distribution in the bodies of mice was held by both intravenous and lymphotropic methods of administration. By means of detection with a photosensitizer (as a marker), the study was conducted on healthy mice and mice with testicle inflammation.